In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Insurance coverage for weight-loss drugs has recently increased, but typically only covers branded versions, according to ...

Novo Nordisk (NVO) is broadening patient access to its FDA-approved weight management drug, Wegovy (semaglutide) 2.4 mg, ...

Eli Lilly will soon launch Mounjaro KwikPen in India. This follows regulatory approval for the diabetes and obesity drug. The ...

Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy ...

India approves Eli Lilly’s Mounjaro KwikPen, a once-weekly injection for type 2 diabetes and obesity, offering dual hormone ...

Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...